Shockwave Medical Named to Fast Company's "Most Innovative Company" List
Shockwave Medical has been named the second most innovative medical device company by Fast Company in its 2022 list. The recognition highlights the impact of their Intravascular Lithotripsy (IVL) technology, which treats severely calcified cardiovascular disease. Since its market introduction in 2017, IVL has expanded globally, being adopted rapidly by thousands of physicians. CEO Doug Godshall emphasized the company's commitment to innovation in improving patient outcomes. This accolade underscores Shockwave's position as a leader in transforming cardiovascular treatments.
- Named the second most innovative medical device company by Fast Company.
- Intravascular Lithotripsy technology has rapidly gained acceptance among physicians globally.
- Recognition emphasizes the company's commitment to innovation in medical treatments.
- None.
Pioneer of IVL Selected as the Second Most Innovative Medical Device Company
SANTA CLARA, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, has been named in Fast Company’s 2022 list of the World’s Most Innovative Companies in the medical device sector and has been recognized for “bringing good vibrations to heart procedures.”
“Shockwave Medical was founded with innovation at our core,” said Doug Godshall, Chief Executive Officer of Shockwave Medical. “We are honored to be recognized not only for pioneering revolutionary and proprietary IVL technology, but also for the ways that innovation permeates every aspect of our business. We are continually evolving and transforming how we do things as we seek to astound our customers with life changing products for the treatment of calcified cardiovascular disease.”
Since first being introduced to the market in 2017, IVL has been launched in the U.S. and nearly 60 other countries across Europe, the Middle East, North and South America and Asia.
“Shockwave has revolutionized the way calcified coronary and peripheral arterial disease is treated by providing a new level of safety in these procedures,” said Dean Kereiakes, M.D., FACC, FSCAI, President of The Christ Hospital Heart and Vascular Institute and Professor of Clinical Medicine, The Ohio State University. “It is no surprise that IVL has been adopted so quickly by thousands of physicians across the globe as they seek to provide the best outcomes in the safest manner possible for their patients who have calcified cardiovascular disease.”
Fast Company’s list of the World’s Most Innovative Companies in medical devices can be found here.
About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.
Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com
Investor Contact:
Debbie Kaster
investors@shockwavemedical.com
FAQ
What recognition did Shockwave Medical receive in 2022?
Why is Shockwave Medical's IVL technology significant?
When was IVL technology launched in the market?
How has IVL technology been adopted by physicians?
What does the recognition by Fast Company reflect about Shockwave Medical?
